Diabetic nephropathy, insulindependent diabetes mellitus, noninsulindependent diabetes mellitus, hypertension, antihypertensive therapy.
he estimated prevalence of insulin-dependent diabetes mellitus (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM) worldwide was reported for 1994 as 11.5 million and 98.9 million persons, respectively.' The authors expect more than a doubling of these prevalence rates by the year 2010, with 23.7 million persons having IDDM and 215.6 million having NIDDM worldwide.
At present, the incidence of diabetes mel-litus in Europe is increasing, both for IDDM and NIDDM. '," In Germany, the prevalence of IDDM patients younger than 40 years and of NIDDM patients is currently calculated at 0.22% and 4.82%, respectively.4,5 Persons with diabetes mellitus are prone to many acute and chronic complications resulting in increased hospitalizations, disability, and death. In the US, where the prevalence of diabetes is approximately 7% in adults, between 1987 and 1992 the total costs of diabetes more than quadrupled, from US $20.4 billion to US $91.8 billion, and the direct medical costs (US $45.2 billion) alone represent 5.8% of the total personal health care expenditures in the USh Diabetic nephropathy, characterized by resistant proteinuria, hypertension, and progressive loss of re-nal function, can develop with either insulin-dependent diabetes mellitus (1DDM) or non-insulin-dependent diabetes mellitus (NIDDM). Recent data from a German clinical study based on more than 700 diabetic patients showed a 48% and a 57% cumulative risk of overt nephropathy (proteinuria) after 25 years of diabetes in IDDM and NIDDM patients, respectively.7 Once initiated, the course of diabetic nephropathy is one of progressive and relentless declining renal function, ending in chronic renal failure. It therefore comes as no surprise to any diabetologist and nephrologist to be told that diabetic nephropathy is now the commonest single cause of end-stage renal disease. The most recent EDTA-Registry data for Europe show that now the number of diabetic patients alive on renal replacement therapy is likely to be approached at 100,000, and the overall rate for new patients accepted for renal replacement therapy was recorded as 17% for diabetics in 1992." The most recent report of the United States Renal Data System (USRDS) shows that in 1992, 33.8%', of all new patients accepted for renal replacement therapy were either IDDM or NIDDM patients.' A recent survey of 28 hemodialysis units all over Germany reported that 24.2% (16.6% to 41.6%) of individuals on dialysis were diabetic patients, of whom 34% had IDDM and 66% NIDDM," and only 57% of IDDM patients and 50% of NIDDM patients survived during the 45-month investigation period." The estimated annual incidence of terminal renal failure with diabetes in a period of January 1993 to June 1994 was recently described as 52 per million per year in the lower Neckar region (Heidelberg, Germany resistence and leads to a worsening of glucose tolerance despite an increase in circulating plasma insulin levels.24 Unfortunately, hyperinsulinemia has been implicated in the development of hypertension, dislipidemia, and atherosclerotic cardiovascular disease.25 Long-term treatment with P-blockers and thiazide diuretics, is associated with a substantially increased risk for diabetes mellitus in both men and women.26 Furthermore, both diuretics and P-blockers promote a more atherogenic plasma lipid profile.27 This may be the reason why, in some large clinical studies of mild essential hypertension, therapy with a P-blocking agents failed to significantly reduce the risk of coronary events.28-30
These observations have led to a reevaluation of the treatment of hypertension in both IDDM and NIDDM patients, with emphasis on the use of angiotensin converting enzyme inhibitors and calcium antagonists, drugs that either enhance insulin sensitivity or are metabolically neutral with regard to both glucose and lipid metabolism.31 Therefore, the following considerations of antihypertensive treatment on the primary, secondary, and tertiary prevention levels are strictly devoted to studies using either ACE inhibitors or calcium antagonists.
Nephroprotective Effects of ACE Inhibitors and Calcium Antagonists
Albuminuria was ascribed a surrogate endpoint for the course of diabetic nephropathy. However, there is now a bulk of evidence that urinary albumin excretion rate will also predict longterm renal function, and may not simply represent a marker of renal disease but may even pathogenetically contribute to its evolution. Reduction in albuminuria predicted diminished progression in diabetic nephropathy3'; short-term antiproteinuric response to antihypertensive treatment predicted long-term GFR decline in patients with nondiabetic renal disease.33 Proteinuria may be a direct cause of renal morbidity and, in particular, glycated albumin affects mesangial cells and may play an important role in the pathogenesis of diabetic nephropathy.34 Multiple studies suggested that ACE inhibitors and certain types of calcium antagonists have distinctive advantages over conventional antihypertensive agents with regard to protecting the residual renal function. Several potential mechanisms may mediate the renal protective actions of both these classes of drugs35-37; some of them are listed in Table 1 .
Based on these pathogenetic considerations, prospective long-term studies with a follow-up of at least 1 year have been meanwhile performed with either ACE inhibitors or calcium antagonists in hypertensive IDDM and NIDDM patients with microalbuminuria (Table 2; Table 3 ). These studies clearly show that strict blood pressure control in this early stage of diabetic nephropathy significantly reduces albuminuria, thus preventing progression to macroalbuminuria (overt nephropathy). 38-45 As far as the effect on kidney function is concerned, the outcome was less clear. Using ACE inhibitors, glomerular filtration rates were either maintained or slightly reduced, whereas, using the calcium antagonist nitrendipine (dihydropyridine type calcium antagonist), a 20% to 40% increase of glomerular filtration rate was observed along with significant reduction of albuminuria. It is still unclear whether the short-term diminution in glomerular filtration rate under the treatment with ACE inhibitors indicates a potentially adverse effect or simply the correction of hyperfiltration. These studies support the hypothesis that angiotensin converting enzyme inhibitors and certain calcium antagonists have a unique ability, independent of their antihypertensive effect, to slow the progression of diabetic nephropathy, which is further substantiated by the interesting findings that treatment with ACE inhibitors or calcium antagonists prevented progression to macroalbuminuria even in normotensive IDDM and NIDDM patients with microalbuminuria46-5" (see Table 4 ). Ten years ago, the beneficial effect of captopril on heavy proteinuria in diabetic patients with overt nephropathy was first described.54 Additional studies have documented the beneficial effect of ACE inhibitors on rnacroalbuminuria and renal function in patients with IDDM and NIDDM."5-57 However, most of these studies have been relatively small, open-label, and of short duration, and have not addressed clinical endpoints such as mortality or progression to end-stage renal disease. In this respect, the paper published by Lewis et al in 1993 was regarded as a landmark study.58 In this study, the effects of captopril in IDDM patients with macroalbuminuria and serum creatinine levels of 2 2.5 mg/dL but normotensive (otherwise treated but not ACE inhibitors or calcium antagonists) were randomized to receive either captopril 25 mg or placebo three times daily. The primary endpoint of the study was the rate of doubling of serum creatinine, secondary endpoints included death or the need for dialysis or transplantation. The average length of follow-up was 3 years, and ACE inhibitor treatment resulted in a 50% risk reduction for primary and secondary end-points. As opposed to ACE inhibitors, the role of calciumantagonists in overt diabetic nephropathy is more unclear because of the lack of large-scale trials. Diltiazem, verapamil, and nicardipine appeared to be of efficacy equal to ACE inhibitors, whereas isradipine was found to be less effective.57,59P62 Studies with the dihydropyridine type calcium antagonist of the first generation, the short-acting nifedipine, are contradictory. In most of the short-term studies on overt albuminuria, a worsening was observed.6"
The recent extended metaanalysis of Weidmann's group revealed the ACE-inhibitors tend to preserve GFR in such patients better than conventional antihypertensive drugs or nifedipine'j4 (Table 5 ). Based on a 2% lowering of the mean blood pressure by placebo treatment and adding data from three different studies with nitrendipine,40,42,45 changes in proteinuria and GFR under treatment with different antihypertensives in diabetic subjects with micro-or macroalbuminuria, the results noted in Table 5 emerged. The differences observed among the group of calcium antagonists may be partially explained by different hemodynamic effects or by proposed different patterns of calcium channels and receptors on different target organs.
Evidence for Additive Nephroprotective Effects of Combinations of ACE Inhibitors and Calcium Antagonists
The request for antihypertensive combination therapy is of clinical relevance because many diabetic patients with hypertension and renal disease require the combination of various antihypertensive drugs to effectively control their hypertension. The concept of combination therapy is attractive also from a pathophysiological aspect, because it is likely that in arresting progression of renal failure the salutary effects of ACE inhibitors and calcium antagonists are complementary and probably synergistic.65
A few studies of combination therapy in animal models have been performed. In an isolated perfused kidney pretreated with an ACE inhibitor, it was found that the efferent arteriolar dilatation was potentiated by adding a calcium antagonist.66 Long-term studies in a canine model of chemically induced diabetes mellitus demonstrated that combinations of an ACE inhibitor and a calcium antagonist had additive antiproteinuric effects.67 Beneficial effects of such combinations on proteinuria, intraglomerular pressure, and histomorphological glomerulosclerosis index were described in subtotal nephrectomy models of the rat.68 Interestingly, a very recent study with nonhypotensive doses of the fixed-dose combination drug VeraTran, of a nondehidropyridine calcium antagonist, verapamil (V), and an ACE inhibitor, trandolapril (T), slowed the development of glomerular sclerosis better than either agent alone in stroke-prone spontaneously hypertensive rats (SHRSP).69 This study further supports the concept that such combinations may have effects on the glomerulus that are independent of blood pressure reduction. Moreover, along with improved kidney function, a significantly increased survival of the study animals was observed.70
Only a few human studies utilizing combination therapy have been reported. Three initial reports of such either short-term or long-term combination therapy in IDDM or NIDDM patients with nephropathy were very promising.60,61,7* Moreover, controlled studies showed that combinations of ACE inhibitors and calcium antagonists mutually reduce somewhat the frequency of their side effects,72 and once again confirmed the metabolic neutrality of such combinations in contrast to combinations of P-blockers and low-dose diuretics in treating hypertensive NIDDM patients."
In summary, it is obvious that a number of arguments can be advanced for combining ACE inhibitors and calcium antagonists. However, whether a combination therapy will offer any benefits in prolonging overall or renal survival is not yet known. CONCLUSION ACE inhibitors and calcium antagonists have no adverse effects on glycemic control or lipid levels and may even improve insulin sensitivity. This further promotes these antihypertensive agents to first-line drugs when treating subjects at risk for metabolic disorders, or persons with diabetes. Moreover, a number of studies exist that show that ACE inhibitors and certain types of calcium antagonists have distinctive advantages over conventional antihypertensive agents with regard to protecting the residual renal function. Experimental and initial clinical trials with combinations of these substances have been reveled additive nephroprotective effects. In addition, prevention would be beneficial in economic terms quite apart from the benefits to the health of individuals and to society. Recently published data provide a basis for preventive strategies both on the secondary and tertiary levels. In particular, aggressive blood pressure control, especially monotherapy or combined therapy with ACE inhibitors and the calcium antagonists of the verapamil, dilthiazem, or nitrendipine class, promises to reduce the risk of diabetic end-stage renal disease by 50% or more. It is thus of particular interest that a recent computer-simulated cost-benefit study on the impact of screening and intervention for microalbuminuria, the indicator and predictor of renal and cardiovascular lesions in general, in IDDM described that assuming treatment effects of 33% and 67%, respectively, the average life expectancy increased by 4 to 14 years, respectively, and the need for dialysis or transplantation decreased by 21% and 63%.74 Costs and savings would balance if the annual rate of increase of albuminuria was decreased from 20% to 18% per year. Moreover, data based on the Lewis et al tria158 suggested that if all diabetic patients (both IDDM and NIDDM) with nephropathy were started on an ACE inhibitor, captopril, in 1994, it would prolong life and save the health care system over US $2 billion by the year 2004.75
To conclude, screening programs for detection of the earliest stage of diabetic nephropathy (microalbuminuria) should be performed on a regular basis and intervention programs including strict blood pressure control, preferably by treatment with ACE inhibitors or certain calcium antagonists, should commence as early as possible and, at the latest, when microalbuminuria becomes apparent. This screening and intervention strategy is likely to improve quality of life, save lives, and lead to considerable economic savings. 
